Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | -1.36% | -2.69% | +11.86% |
03-04 | North American Morning Briefing : Stock Futures -2- | DJ |
02-28 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 2M 160M | Sales 2025 * | 2.5M 200M | Capitalization | 553M 44.18B |
---|---|---|---|---|---|
Net income 2024 * | -225M -17.97B | Net income 2025 * | -259M -20.68B | EV / Sales 2024 * | 11.9 x |
Net cash position 2024 * | 529M 42.27B | Net cash position 2025 * | 623M 49.72B | EV / Sales 2025 * | -27.8 x |
P/E ratio 2024 * |
-2.49
x | P/E ratio 2025 * |
-2.37
x | Employees | 224 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.2% |
1 day | -1.36% | ||
1 week | -2.69% | ||
Current month | -2.69% | ||
1 month | -2.69% | ||
3 months | +4.33% | ||
6 months | +38.22% | ||
Current year | +11.86% |
Managers | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 30/04/21 |
Charles Newton
DFI | Director of Finance/CFO | 53 | 31/01/21 |
Stephen Hill
COO | Chief Operating Officer | 53 | 31/05/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 30/04/21 |
Robert Nelsen
BRD | Director/Board Member | 60 | 31/08/18 |
Otis Brawley
BRD | Director/Board Member | 64 | 31/03/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.01% | 237 M€ | +2.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 2.17 | -1.36% | 352,183 |
25/04/24 | 2.2 | -4.35% | 540,834 |
24/04/24 | 2.3 | -5.74% | 775,286 |
23/04/24 | 2.44 | +1.24% | 687,131 |
22/04/24 | 2.41 | +8.07% | 958,851 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 553M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LYEL Stock